Routine

Colorectal cancer screening

CRC screening · Gastroenterology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Population and risk-based screening detects early cancer and removes adenomas to reduce incidence and mortality. Faecal immunochemical testing (FIT) underpins population programmes, with colonoscopy for positive tests and higher-risk groups.

Red flags

  • Rectal bleeding, change in bowel habit, weight loss, anaemia (urgent diagnostic referral, not screening)
  • Positive FIT (needs colonoscopy)
  • Strong family history / known hereditary syndrome
  • Mass or stricture at colonoscopy

Assessment

Differential diagnosis

  • Sporadic average-risk population
  • Family history / Lynch syndrome / FAP (high-risk pathways)
  • Inflammatory bowel disease surveillance (separate programme)
  • Symptomatic patients (diagnostic, not screening, pathway)

Investigations

  • Faecal immunochemical test (FIT) as primary screen
  • Colonoscopy for FIT-positive and high-risk individuals
  • CT colonography where colonoscopy incomplete/contraindicated
  • Genetic testing/counselling for suspected hereditary syndromes
  • Family history assessment to assign risk category

Management

  • Identify the individual's risk category: average, increased (family history), or high (hereditary syndrome, IBD)
  • Offer population FIT-based screening at the programme's defined age range and interval
  • Refer FIT-positive individuals promptly for colonoscopy
  • At colonoscopy, resect all adenomas and classify findings to set surveillance
  • For significant family history, start colonoscopic screening earlier and at shorter intervals
  • Enter confirmed Lynch syndrome into 2-yearly colonoscopy with earlier commencement
  • Manage FAP with appropriate colonoscopic/flexible sigmoidoscopy surveillance and surgical planning
  • Counsel high-risk patients and refer for genetic testing where indicated
  • Use CT colonography if colonoscopy is incomplete or unsuitable
  • Ensure symptomatic patients enter the urgent diagnostic (not screening) pathway
  • Reinforce modifiable risk reduction (smoking, alcohol, diet, activity, weight)

Drugs & doses

Aspirin — considered for chemoprevention in Lynch syndrome (specialist decision)
Bowel preparation agents for colonoscopy (e.g. macrogol-based)

Disposition

Population screening programme; high-risk and hereditary cases to genetics and specialist surveillance.

Complications & pitfalls

  • Interval cancers (missed/declined screening)
  • Colonoscopy risks: bleeding, perforation
  • Over-surveillance harms and resource burden
  • Anxiety/false positives

Exam pearls

  • Symptomatic patients need the urgent diagnostic pathway — screening is for asymptomatic individuals
  • FIT is central to modern population screening and triages who needs colonoscopy
  • Lynch syndrome warrants earlier, 2-yearly colonoscopy and consideration of aspirin chemoprevention
  • Adenoma removal at colonoscopy is what prevents cancer, not just detection

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.